Related Experiment Video

Updated: Apr 17, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.9K

An interesting perspective on a well-studied pathway: does type III TGF-Β receptor have therapeutic potential?

Philip C Trackman1

  • 1Department of Molecular and Cell Biology, Henry M. Goldman School of Dental Medicine, 700 Albany Street; W-201, Boston, MA, 02118, USA, trackman@bu.edu.

Journal of Cell Communication and Signaling
|February 22, 2015
PubMed

Insights

The type III TGF-β receptor shows promise for treating and predicting outcomes in breast cancer patients. Further research into this receptor could lead to new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Transforming growth factor-beta (TGF-β) signaling pathways are crucial in cellular processes.
  • Dysregulation of TGF-β signaling is implicated in various cancers, including breast cancer.
  • The type III TGF-β receptor (TβRIII) plays a role in modulating TGF-β signaling.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting the type III TGF-β receptor in breast cancer.
  • To evaluate the prognostic value of the type III TGF-β receptor in breast cancer patients.

Main Methods:

  • Analysis of TβRIII expression in breast cancer cell lines and patient samples.
  • In vitro studies assessing the effects of TβRIII modulation on cancer cell behavior.
  • Correlation analysis between TβRIII expression levels and clinical outcomes.

Main Results:

  • TβRIII expression levels were found to be altered in breast cancer tissues.
  • Modulation of TβRIII significantly impacted breast cancer cell proliferation and migration.
  • Higher TβRIII expression correlated with specific clinical prognostic indicators.

Conclusions:

  • The type III TGF-β receptor represents a potential therapeutic target for breast cancer.
  • TβRIII may serve as a valuable prognostic biomarker for breast cancer patients.
  • Targeting TβRIII warrants further investigation for novel breast cancer treatment strategies.

More Related Videos

Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay11:38

Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay

Published on: September 14, 2021

3.9K
Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System11:06

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System

Published on: July 30, 2018

11.2K

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
11.1K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
5.1K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
3.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
820